BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 29, 2016
View Archived Issues
DKN-01 plus paclitaxel well tolerated in patients with EC or GEJ
Read More
The Hereditary Neuropathy Foundation announces partnership with Acetylon Pharmaceuticals
Read More
Chugai reviews key regulatory and pipeline events of fourth quarter 2015
Read More
Avax Technologies announces results of its OVAX phase I/II clinical trial
Read More
Akashi Therapeutics suspends dosing and enrollment in HT-100 trial
Read More
Synthetic lethality approach used to identify antibacterial compounds
Read More
FDA grants breakthrough therapy designation for Lynparza as treatment of prostate cancer
Read More
Genticel reports phase II trial results for ProCervix
Read More
Sophiris reports initial data from phase IIa trial of topsalysin in prostate cancer
Read More
Gruenenthal discloses phosphodiesterase 4B inhibitors
Read More
Novogen patent reports tropomyosin alpha-3 chain inhibitors
Read More
HEC Pharm presents FLT3 inhibitors
Read More
Biogen divulges IRAK-4 inhibitors
Read More
Cancer Research Technology and MSD form PRMT5 inhibitor collaboration
Read More
Phase I study of MERS vaccine begins
Read More
Radius Health announces clinical collaboration to evaluate RAD-1901 combination regimens
Read More
Giant multivalent glycofullerenes inhibit cell infection by Ebola virus
Read More
FDA grants fast track designation to IMC-1 combination for fibromyalgia
Read More
FDA approves Merck & Co.'s Zepatier for HCV infection
Read More
FDA approves Onzetra Xsail for acute treatment of migraine
Read More
Phase III Opdivo trial meets endpoint, stopped early
Read More
Cerenis starts phase III trial of CER-001 in familial primary hypoalphalipoproteinemia
Read More
ENB Therapeutics' ENB-001 granted FDA orphan designation for melanoma
Read More
Agilis and NTU enter collaboration for AADC deficiency gene therapy
Read More
FDA approves Halaven in new indication
Read More
Biofrontera reports promising phase III results for Ameluz in basal cell carcinoma
Read More
FDA says Exelixis's NDA for cabozantinib now complete
Read More